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Abstract
Background: The aim of this study was to evaluate the efficacy and tolerability of photodynamic therapy (PDT)
compared to intravitreal vascular endothelial growth factor (VEGF) inhibitors in the treatment of polypoidal
choroidal vasculopathy (PCV).
Methods: Relevant studies were selected through an extensive search of the PubMed, EMBASE, Web of Science, and
Cochrane Library databases. Outcomes of interest included visual outcomes, anatomic variables, and adverse events.
Results: Six studies enrolling a total of 346 patients were included. The weighted mean differences (WMDs) of the
mean changes in LogMAR VA when comparing PDT with anti-VEGF were −0.02 (95 % confidence interval [CI]:
−0.12–0.08) at 3 months, 0.02 (95 % CI: −0.12–0.16) at 6 months, 0.02 (95 % CI: −0.15–0.18) at 12 months, and −0.17
(95 % CI: −0.90–0.55) at 24 months. There were no significant differences between the two groups at any of the
time points. PDT was found to be associated with greater reduction of central retinal thickness (CRT) at six months
(WMD: 44.94; 95 % CI: 16.44–73.44; P = 0.002), and it was superior to anti-VEGF therapy in achieving complete
polyp regression (odd ratio, OR: 6.85; 95 % CI: 2.15–21.79; P = 0.001).Rates of adverse events did not differ
significantly between the two treatments.
Conclusions: PDT appeared to result in greater CRT reduction at six months and higher polyp regression rate.
However, the two treatments appear to be comparable in terms of best corrected visual acuity change and
adverse events.
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Background
Polypoidal choroidal vasculopathy (PCV) is a distinct
choroidal abnormality characterized by an abnormal
branching vascular network in polypoidal structures [1].
It usually causes a decrease in vision through its serious
complications such as subretinal hemorrhage, macular
edema, and retinal pigment epithelial detachment [2].
Different forms of PCV have different prognoses. The
natural course of PCV, which is characterized by clus-
tered polypoidal choroidal lesions, is always related to a
poor prognosis [3]. Several studies have reported that
PCV is more prevalent in Japanese and other Asian pop-
ulations than in Caucasian populations [4–6].
Regarding the treatment modalities for PCV, photo-
dynamic therapy (PDT) has been widely used and has
shown encouraging results in the regression of polypoi-
dal lesions and stabilization or improvement of visual
acuity [7–9]. However, recurrent or newly developed
polypoidal lesions may negatively affect the efficacy of
this treatment method [10, 11].
Anti-vascular endothelial growth factor (VEGF) ther-
apy is another treatment modality for PCV that is being
investigated [12–14]. Intravitreal injection of anti-VEGF
agents, including bevacizumab [15] and ranibizumab
[16], were tested against PDT and found to reduce ex-
udative fluid, but they did not affect the original abnor-
mal vasculatures [17].
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The optimum treatment for PCV remains controver-
sial. To date, a number of studies have compared the
anatomic and functional outcomes of PDT and intravit-
real injection of anti-VEGF agents for treating PCV [7,
18–22]. However, most are studies with small sample
sizes, and no definitive conclusions regarding objective
differences in outcomes have been reached. Some of the
studies found that PDT resulted in a significantly better
outcome than anti-VEGF treatment [7, 22], whereas
other studies reported different results [19, 20]. There-
fore, we performed a systematic review and meta-
analysis based on relevant published controlled clinical
trials to evaluate whether PDT offers any advantages
over anti-VEGF in terms of anatomic and functional
outcomes when treating PCV.
Methods
This meta-analysis was performed according to a prede-
termined protocol, described below. In addition, stand-
ard systematic review guidelines outlined by the
Cochrane Handbook for Systematic Reviews of Interven-
tions and Preferred Items for Systematic Reviews and
Meta-Analysis (PRISMA) Statement were followed [23].
Literature search
A literature search of PubMed, ISI Web of Science,
EMBASE, and the Cochrane library was performed to
identify relevant studies. The following terms were used
for the searches: (“polypoidal choroidal vasculopathy”
OR PCV) AND (“angiogenesis inhibitors” OR “endothe-
lial growth factors” OR VEGF OR lucentis OR ranibizu-
mab OR bevacizumab OR avastin) AND (“photodynamic
therapy” OR PDT). The websites of professional associa-
tions and Google Scholar were also searched for add-
itional information. Once relevant articles were
identified, their reference lists were searched for add-
itional articles. The final search was carried out in
March 2014, without restrictions regarding publication
year, language, or methodological filter.
Inclusion and exclusion criteria
The following inclusion criteria were used: (i) study type:
comparative studies; (ii) population: treatment-naive pa-
tients with PCV; (iii) intervention: PDT alone versus
anti-VEGF alone; and (iv) outcome variables: evaluation
of at least one of the outcomes of interest mentioned
below. Editorials, letters to the editor, review articles,
case reports, meeting abstracts, and animal experimental
studies were excluded.
Outcome measures
The following outcomes were used to compare PDT and
anti-VEGF. (1) Visual outcomes: mean visual acuity (VA)
change at three, six, 12, and 24 months; and proportion of
eyes with improved, stable, and deteriorated vision at end-
point. After assessing VA at each follow up visit, the pa-
tients were categorized into three groups based on their
VA change from baseline: improved, stable, and deterio-
rated VA. The VA was considered to be improved or dete-
riorated when the change in the logMAR VA exceeded 0.3
units. (2) Anatomical outcomes: mean change in central
retinal thickness (CRT) at three, six, and 12 months and
regression rates of polyps. (3) Adverse events: incidence of
retinal hemorrhage.
Data extraction
Two reviewers (Z.M.W. and M.Y.) independently ex-
tracted data from the included studies, and disagree-
ments were resolved by discussion until a consensus was
reached. The following information was extracted from
each study: first author; year of publication; study design;
location of the trial, follow up; baseline patient charac-
teristics; inclusion and exclusion criteria; and outcomes
of interest. Patients reporting adverse events were also
recorded.
Assessment of methodology quality
The qualities of the clinical trials included were assessed
by two independent observers (Z.M.W. and M.Y.) using
a previously reported quality assessment system for both
randomized and nonrandomized studies [24]. The sys-
tem includes 27 items distributed among five subscales:
reporting (ten items), external validity (three items), bias
(seven items), confounding (six items), and power (one
item). Any discrepancy in qualitative assessment be-
tween the two observers was discussed, and a consensus
was reached. The total score for each trial was expressed
as a percentage of the maximum achievable score. A
score not lower than 50 % is considered good quality.
Statistical analysis
Data from this meta-analysis are presented in accord-
ance with PRISMA guidelines [25]. Weighted mean dif-
ferences (WMDs) and odds ratios (ORs) were used to
compare continuous and dichotomous variables, re-
spectively. All outcomes were reported with 95 % confi-
dence interval (CI). Considering the different clinical
characteristics among study groups and the different
sample sizes, we assumed that heterogeneity was present
even when no statistical significance was identified, and
we decided to combine data by using a random effects
model to achieve more conservative estimates [26]. Stat-
istical heterogeneity between studies was assessed using
the chi-squared test, and the quantity of heterogeneity
was evaluated using the I2 statistic. A p value <0.05 was
considered statistically significant. All statistical analyses
were performed using Stata (version 12; StataCorp, Col-
lege Station, TX).
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Sensitivity analysis and publication bias
A sensitivity analysis was undertaken to evaluate the ef-
fect of the methodological characteristics of controlled
clinical trials in terms of trial design and different anti-
VEGF agents. Potential publication bias was evaluated
with Begg’s and Egger’s tests [27, 28].
Results
Literature search
A total of 428 papers were identified by our literature
search, of which 209 were excluded as duplicate studies
and 197 were excluded based on the titles and abstracts.
The remaining 22 studies were retrieved for full-text
Fig. 1 Flowchart of publication search and selection
Table 1 Characteristics of included studies
First Author
(year)















Mitamura(2010)22 Retro 1 Japan TD-
OCT
49/49 22/22 7/42 5/17 73.0/
69.6
3/3
Rouvas (2011)7 Retro 2 Greece SD-
OCT
11/11 10/10 6/5 5/5 62.9/
66.5
12/12




21/21 21/21 15/6 15/6 62.2/
69.3
6/6














Kang (2014)18 Retro 1 Korea TD-
OCT




PDT photodynamic therapy; VEGF vascular endothelial growth factor; mo months; Retro retrospective comparative study; TD-OCT time-domain optical coherence
tomography; SD-OCT spectral-domain optical coherence tomography; RCT prospective randomized controlled
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review. Eleven of the studies were excluded because they
focused on combined therapy, three case reports were
excluded, and two articles were excluded because they
included non-treatment-naive patients. Thus, a final
total of six studies published between 2010 and 2013
were included in this meta-analysis [7, 18–22]. The trial
selection process is shown in Fig. 1.
Study characteristics and quality
The characteristics of the included studies are shown in
Tables 1 and 2. A total of 346 eyes of 346 patients were
enrolled, with the mean age ranging from 62.2 to
75.4 years. The duration of the studies ranged from
three to 24 months. Two trials had a prospective, paral-
lel, randomized design, and four had a retrospective,
nonrandomized design. The quality assessment is sum-
marized in Table 3. The Downs and Black scores of all
of the studies were over 16 (50 %), and the scores of
both of the randomized clinical trials (RCTs) were over
24 (75 %).
Visual outcomes
VA was the most important criterion for evaluating effi-
cacy. Differences in mean LogMAR VA changes between
the two groups are presented in Table 4. No significant
differences in BCVA change were found in the PDT
group compared with the anti-VEGF group at three
months (WMD, −0.02; 95 % CI, −0.12–0.08); six months
(WMD, 0.02; 95 % CI, −0.12–0.16); 12 months (WMD,
Table 2 Characteristics of lesions and treatment exposures included in the meta-analysis












PDT 3718 ± 1665 PDT (6 mg/
m2)
1PDT 3 Presence of reddish-orange lesions; recurrent serosanguinous RPE
detachments; dilated network of inner choroidal vessels with ter-
minal hyperfluorescent aneurysm-like dilatations (polyps) on ICGA.
Anti-
VEGF
3651 ± 1833 IVB 1.25 mg 3IVB 3
Rouvas
(2011)
PDT NA PDT (6 mg/
m2)
1.82(1–3)PDT 12 Identification of polyps and interconnecting vessels on the ICGA;
presence of subretinal hemorrhages and/or exudation in the
macula based on clinical examination
Anti-
VEGF













IVR 0.5 mg 2.5 IVR 12
Koh
(2012)
PDT <5400 PDT (6 mg/
m2) + sham
1.7(1–4) PDT 6 Presence of early subretinal focal ICGA hyperfluorescence; at least
one of the followingclinical criteria: presence of pulsatile polyp;
presence of hypofluorescent halo; orange subretinal nodules in
fundus photographAnti-
VEGF





PDT 3640 ± 2120 PDT (6 mg/
m2)
1.52 ± 0.66 PDT 24 presence of clinical, OCT, FA and confocal ICGA findings showing
a branching vascular network and polypoidal structures
Anti-
VEGF







2.56 ± 0.38 PDT 24 PCV with subfoveal leakage on FA; presence of branching








10.12 ± 1.46 IVR/
IVB
24
GLD greatest linear dimension; SD standard deviation; PCV polypoidal choroidal vasculopathy; PDT photodynamic alone; RPE retinal pigment epithelium; VEGF
vascular endothelial growth factor; IVB intravitreal bevacizumab; ICGA indocyanine green angiography; NA not available; IVR intravitreal ranibizumab; OCT optical
coherence tomography; FA fluorescein angiography
Table 3 Quality scoring components for six clinical trials
included
Quality score component Score
First Author(year) I II III IV V Over all Percentage
Mitamura(2010) 8 2 4 2 1 17 53.13 %
Rouvas (2011) 9 2 4 2 1 18 56.25 %
Koh (2012) 11 3 5 3 2 24 75.00 %
Oishi (2013) 11 3 5 5 2 26 81.25 %
Inoue (2013) 9 2 4 2 2 19 59.38 %
Kang (2014) 9 2 4 3 2 20 62.50 %
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0.02; 95 % CI, −0.15–0.18), and 24 months (WMD,
−0.17; 95 % CI, −0.90–0.55) post-treatment. Substantial
statistical heterogeneity was observed across studies at
the 6-, 12- and 24-month time points. We then divided
the studies into subgroups according to study design
(retrospective and randomized) and different anti-VEGF
agents. There were no statistically significant differences
in mean BCVA changes between the PDT group and the
anti-VEGF group at all subgroups, with the exception of
one RCT subgroup at the 12-month time point. When
VA change was treated as a categorical variable, the per-
centages of improved, stable, and deteriorated VA at
Table 4 Pooled estimates for BCVA change from baseline for PDT versus anti-VEGF








LogMAR Change in both Groups (PDT group vs anti-VEGF group) (3mo)
Design
All trials 5 −0.02 (−0.12, 0.08) Z =0.45, P =0.653 6.77 0.148 40.9 %
Retro 4 −0.05 (−0.18, 0.07) Z =0.85, P =0.407 5.10 0.165 41.2 %
RCT 1 0.05 (−0.07, 0.17) Z =0.83, P =0.407 -
Anti-VEGF agents
All trials 5 −0.02 (−0.12, 0.08) Z =0.45, P =0.653 6.77 0.148 40.9 %
Ranibizumab 3 −0.03 (−0.20, 0.13) Z =0.39, P =0.694 6.71 0.035 70.2 %
Non- Ranibizumab 2 −0.02 (−0.16, 0.12) Z =0.32, P =0.749 0.02 0.859 0.00 %
LogMAR Change in both Groups (PDT group vs anti-VEGF group) (6mo)
Design
All trials 4 0.02 (−0.12, 0.16) Z =0.23, P =0.817 7.60 0.055 60.5 %
Retro 3 −0.03 (−0.22, 0.17) Z =0.25, P =0.800 5.74 0.057 65.2 %
RCT 1 0.10 (−0.02, 0.22) Z =1.66, P =0.097 -
Anti-VEGF agents
All trials 4 0.02 (−0.12, 0.16) Z =0.23, P =0.817 7.60 0.055 60.5 %
Ranibizumab 3 0.02 (−0.15, 0.20) Z =0.27, P =0.787 7.21 0.027 72.3 %
Non- Ranibizumab 1 −0.03 (−0.27, 0.21) Z =0.25, P =0.806 -
LogMAR Improvements in both Groups (PDT group vs anti-VEGF group) (12mo)
Design
All trials 4 0.02 (−0.15, 0.18) Z =0.20, P =0.839 10.43 0.015 71.2 %
Retro 3 −0.04 (−0.24, 0.16) Z =0.40, P =0.690 5.99 0.050 66.6 %
RCT 1 0.15 (0.03, 0.27) Z =2.49, P =0.013 -
Anti-VEGF agents
All trials 4 0.02 (−0.15, 0.18) Z =0.20, P =0.839 10.43 0.015 71.2 %
Ranibizumab 3 0.03 (−0.17, 0.24) Z =0.31, P =0.760 9.63 0.009 79.0 %
Non- Ranibizumab 1 −0.05 (−0.29, 0.19) Z =0.41, P =0.682 -
LogMAR Improvements in both Groups (PDT group vs anti-VEGF group) (24mo)
All trials 2 −0.17 (−0.90, 0.55) Z =0.47, P =0.638 19.1 P < 0.001 94.8 %
LogMAR Change as Categorical Variable
Proportion of eyes with improved vision
final visit 5 1.24 (0.54, 2.85) Z =0.51, P =0.610 7.47 0.113 46.4 %
Proportion of eyes with deteriorated vision
final visit 5 1.40 (0.42, 4.73) Z =0.55, P =0.586 11.23 0.024 64.4 %
Proportion of eyes with stable vision
final visit 5 0.56 (0.29, 1.10) Z =1.67, P =0.094 6.82 0.145 41.4 %
PDT photodynamic therapy; VEGF vascular endothelial growth factor; WMD weighted mean differences; OR odds ratio; CI confidence interval; Retro retrospective
comparative study; RCT prospective randomized controlled trial
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final visits were compared. The rates of improved, stable,
and deteriorated BCVA were comparable between the
two groups (Table 4).
Central retinal thickness
CRT was defined as the distance between the internal
limiting membrane and the inner surface of the RPE,
and measured manually at the fovea. CRT was reported
as the mean change from baseline to follow up month
and was measured by optical coherence tomography
(OCT). The pooled results revealed that at the six-
month follow up, change in CRT was significantly higher
in the PDT group than in the anti-VEGF group (WMD,
44.94; 95 % CI, 16.44–73.44). However, this difference
was not statistically significant at three and 12 months,
with WMDs of 18.69 (95 % CI: −0.83–38.20) and
13.91(95 % CI: −42.14–69.97), respectively. No substan-
tial statistical heterogeneity was observed across studies
at most time points, with the exception of the12-month
time point. We also divided the studies into subgroups
according to study design (retrospective and random-
ized). The subgroup analysis indicated that none of the
subgroups materially altered the pooled results. Stratifi-
cation by different type of OCT also showed that differ-
ent type of OCT did not alter the pooled results at any
follow up time point (Table 5).
Regression rates of polyps and adverse events
Five studies reported the regression rates of polyps at
the follow up end point, and PDT was superior to anti-
VEGF therapy in achieving complete polyp regression
(OR: 6.85; 95 % CI: 2.15–21.79; p =0.001) (Fig. 2). There
were insufficient data about adverse effects, therefore,
most of adverse effects were not pooled in the present
meta-analysis. Retinal hemorrhage was the most com-
mon complication; the pooled data showed no signifi-
cant difference between the two groups (OR: 2.44; 95 %
CI: 0.83–7.1; p = 0.104).











All trials 5 18.69 (−0.83, 38.20) Z =1.88, P =0.061 2.36 0.670 0.00 %
Retro 3 22.75 (−0.96, 44.54) Z =1.05, P =0.141 1.56 0.459 0.00 %
RCT 2 2.24 (−41.62, 46.09) Z =0.10, P =0.920 0.13 0.719 0.00 %
Type of OCT
TD-OCT 3 10.47 (−30.90, 51.85) Z =0.50, P =0.620 1.29 0.526 0.00 %
SD-OCT 2 21.03(−1.09, 43.17) Z =1.86, P =0.062 0.88 0.348 0.00 %
CRT Reduction (6mo)
Design
All trials 4 44.94 (16.44, 73.44) Z =3.09, P =0.002 4.30 0.231 30.3 %
Retro 2 36.87 (14.58, 59.16) Z =3.24, P =0.001 0.65 0.421 0.00 %
RCT 2 66.62 (3.42, 129.81) Z =2.07, P =0.039 2.05 0.152 51.3 %
Type of OCT
TD-OCT 2 22.15 (2.98, 67.30) Z =2.06, P =0.038 0.17 0.678 0.00 %
SD-OCT 2 62.13 (8.19, 116.07) Z =2.26, P =0.024 3.08 0.079 67.5 %
CRT Reduction (12mo)
Design
All trials 3 13.91(−42.14, 69.97) Z =0.49, P =0.627 8.48 0.014 76.4 %
Retro 2 36.03 (−13.52, 85.58) Z =1.43, P =0.154 2.48 0.115 59.6 %
RCT 1 13.91 (−42.14, 69.97) Z =1.00, P =0.315 - -
Type of OCT
TD-OCT 1 1.35 (−60.65, 63.35) Z =0.04, P =0.966 - - -
SD-OCT 2 16.70 (−65.61, 99.00) Z =0.40, P =0.691 6.92 0.009 85.6 %
CRT central retinal thickness; PDT photodynamic therapy; VEGF vascular endothelial growth factor; WMD weighted mean differences; CI confidence interval; Retro
retrospective comparative study; RCT prospective randomized controlled trial; OCT optical coherence tomography; TD-OCT time-domain optical coherence tomog-
raphy; SD-OCT spectral-domain optical coherence tomography
Yong et al. BMC Ophthalmology    Page 6 of 9
Publication bias
Assessment of publication bias using Egger’s and Begg’s
tests based on mean changes in LogMAR VA at three
months showed that there was little potential publica-
tion bias among the included trials (Egger’s test, p =
0.327; Begg’s test, p =0.221).
Discussion
PCV is a choroidal vascular disorder that can be treated
effectively by PDT or anti-VEGF therapy. For many
years, the scientific debate regarding the comparative ef-
fectiveness of PDT and anti-VEGF treatment for PCV
has remained unsettled. In the present meta-analysis, we
reviewed the literature on the efficacy and safety of PDT
and anti-VEGF treatment in the management of PCV.
The results of this systematic review showed that PDT
was more effective in CRT reduction than anti-VEGF at
six months post-treatment and that PDT was more ef-
fective than anti-VEGF in achieving regression of polyps.
However, these two treatment procedures appear to be
equivalent in terms of BCVA change at all follow up
time points. It should be noted that the frequency of
retreatments for both PDT and anti-VEGF groups is not
uniform in different studies. This might be a confounder
between the study groups. However, the results from our
subgroup analyses were quite similar and robust. None
of the outcome results were significantly modified by re-
search design or different anti-VEGF agents used, except
one subgroup, which included only one RCT trial.
VA, a primary measure of treatment efficacy, is an ex-
ceedingly important outcome. Our meta-analysis of all
changes in logMAR BCVA during the follow up months
revealed that PDT was comparable with anti-VEGF ther-
apy at all follow up time points. The direct effect of
PDT on polypoidal lesions and the subsequent reso-
lution of exudative fluid might lead to a favorable visual
outcome. As for anti-VEGF, the rapid resolution of ex-
udative fluid and retinal edema might be the cause of
the favorable BCVA. CRT is another strong prognostic
measure of PCV severity. At six months, significant de-
creases in CRT were found in the PDT group compared
with the anti-VEGF group. The fact that PDT induces
more CRT reduction, but not more BCVA change, than
anti-VEGF confirmed the notion that reduction of CRT
does not necessarily indicate a good visual outcome.
A number of studies have shown encouraging results
for PDT’s effect on the vascular lesions of PCV, with
complete regression of the polypoidal lesions achieved
with fewer sessions in many cases [2, 7]. The pooled re-
sult of this meta-analysis also showed that PDT resulted
in superior efficacy in terms of polyp regression com-
pared to anti-VEGF therapy, which is consistent with
most studies. This finding seemed reasonable, because
PDT is known to be effective for treating PCV as a result
of its photothrombotic effect on choroidal vascular le-
sions with polyps [2]. On the other hand, anti-VEGF
treatment has its own inherent merits of reducing ex-
udative lesions, leakage, resolving fluids, and improving
VA, but it is ineffective for polyp regression [7, 21]. In
this context, treatment with both PDT to resolve the
polypoidal lesions and anti-VEGF agents to reduce the
exudative lesions might be an ideal therapy method
Fig. 2 Forest plot of the risk estimates of the complete polyp regression rate between PDT and anti-VEGF
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when treating PCV. The previous meta-analysis demon-
strated that a combined-treatment appeared to result in
better visual acuity and lower retinal hemorrhage [29].
Several studies have reported that PDT usually has
more vision-threatening side effects, such as the induc-
tion of severe subretinal hemorrhage, than anti-VEGF
therapy [30,31]. Nevertheless, the present meta-analysis
showed that the incidence of subretinal hemorrhage
complication is comparable between the two treatment
methods. Of note, the present meta-analysis only in-
cluded two studies, the small sample size should also be
taken into consideration and this finding should be
interpreted with caution.
Substantial heterogeneity was observed among studies
when comparing the efficacy of PDT and anti-VEGF,
which was not surprising, given the differences in the
various matching criteria and non-standardized meas-
urement of outcomes. Using the random-effects model
to pool the data might reduce, but will not abolish, the
effect of heterogeneity.
Our study has a number of strengths. First, the meta-
analysis was a direct comparison between PDT and anti-
VEGF, rather than an indirect comparison. Second, the
meta-analysis had strict inclusion and exclusion criteria;
we excluded two studies that included patients who had
previously received PDT or anti-VEGF treatment [32,
33]. Third, we strictly followed the Cochrane Handbook
for Systematic Reviews of Interventions and the
PRISMA statement, including the literature search, data
extraction, quality assessment, and statistical analysis,
thereby making our conclusions more scientific and reli-
able. Thus, this meta-analysis provides the most up-to-
date information in this area.
There were some limitations to this study. First, all of
the included studies were retrospective, except for two
RCTs with small sample sizes. Inadequate random se-
quence generation and blinding could result in selection
bias, as patients with worse visual prognoses might be
offered the combination treatment. Nonetheless, the
major characteristics of the eyes in the two groups were
comparable at baseline, and therefore, selection bias was
less likely to occur. Second, the anti-VEGF group used
either bevacizumab or ranibizumab as an anti-VEGF
agent, and there might be a difference between the two
agents when treating PCV. However, subgroup analysis
showed that they had similar results. Therefore, the ef-
fect of different anti-VEGF agents might not significantly
affect the results. The third limitation was the presence
of between-studies heterogeneity. A random effects
model was used when statistically significant heterogen-
eity was encountered. Fourth, as we could not gain ac-
cess to unpublished results, publication bias cannot be
fully excluded. A fifth limitation is that the analyses of
VA change, which was treated as a categorical variable,
regression rates of polyps, and adverse events were
based on data pooled from trials of different durations
due to a lack of reported data in all follow-up phases. It
was a compromise proposal to choose the follow-up
end-point data. Lastly, to avoid publication bias, we con-
ducted not only an electronic search, but also a manual
search in order to identify all potentially relevant arti-
cles, including both published and unpublished studies.
Unfortunately, it is possible that we may have failed to
include some papers, especially those published in other
languages.
Conclusions
To the best of our knowledge, this is the first systematic
review to focus on the question of whether PDT or anti-
VEGF treatment is more effective for PCV. The results
showed that PDT produced better CRT reduction at six
months post-treatment, as well as higher rates of poly-
poidal regression, than anti-VEGF treatment. Despite
these encouraging findings, the inherent limitations of
the included studies should be considered, and conclu-
sions drawn from our pooled results should be inter-
preted with caution. Future large-volume, well-designed
RCTs with extensive follow-up are needed to confirm
and update the findings of this analysis.
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